4-6 hot flash episodes a week starting in February. I’m 38, T2D, on tirzepatide 7.5mg, and my gynecologist confirmed perimenopause is likely based on elevated FSH. Not what I had on the bingo card this year. The thing I haven’t seen discussed anywhere: my Libre 3 is showing a glucose bump of 15-25 points within 20-30 minutes of a hot flash. Not every episode, but consistently enough to flag as a pattern across 6 weeks of logging. Working theory is cortisol - vasomotor event triggers a stress hormone spike, glucose follows. I’ve been tagging these as “HF_glucose_event” in my spreadsheet and it’s showing up in roughly 60% of episodes.
This matters for T2D management bc those mini-spikes have no food trigger. If I’m only reading meal logs I’d never identify them. Context column is doing a lot of work. Looking at fezolinetant as a non-hormonal option since I don’t want estrogen complicating my current metabolic picture. My endo and gynecologist haven’t coordinated on this yet, which feels like a structural gap in how overlapping conditions get managed. If anyone else is running CGM data alongside vasomotor tracking, I’d genuinely want to know what you’re seeing.
Perimenopause at 38 while actively managing T2D on tirz - the overlap between those two conditions is barely documented, and the fact that you’re six weeks into correlating vasomotor events to CGM readings is more rigorous than most published case data. Your cortisol hypothesis is credible; I track cycle-phase glucose variation and saw a consistent luteal bump at 7.5mg that narrowed after titrating up, which makes me think dose-offset on hormonal fluctuation is real. The caveat I’d raise: your 40% of hot flash episodes without a glucose response is also worth logging separately and treating as signal, not noise. If those non-spiking episodes cluster around time-of-day or injection proximity, you may have a secondary variable worth naming before attributing the whole pattern to cortisol alone. The endo and gynecologist not coordinating yet is a structural problem, not a you problem.
The case for logging the 40% non-spikers separately is solid, but hot flash intensity is a confound I haven’t fully accounted for. A mild flush and a drenching sweat aren’t the same cortisol load. Severity tagging goes on the spreadsheet next.
The 40% non-spikers are going to do a lot of analytical work once you add severity tags, bc if they cluster toward mild flushes that actually strengthens the cortisol-hepatic output model rather than muddying it. A drenching sweat and a warm flush are probably different sympathoadrenal events, and if glucose delta tracks severity, you’d have a cleaner mechanism story than the current 60/40 split suggests. One thing worth layering in if your cycle is still irregular: luteal-phase baseline elevation might be compounding on some of those vasomotor episodes. My luteal bump at 7.5mg tirz was roughly 10 mg/dL - not huge, but if a hot flash lands in late luteal, the starting glucose changes how the delta reads. Early perimenopause cycles can be irregular enough that phase tagging gets messy, but when you can pin it, it’s worth adding to the context column alongside severity. The cross-correlation summary in CareClinic’s medication tracker is actually where I’d want to look at this kind of multi-variable logging - if you can pull HF severity tag against glucose delta across enough episodes you’d start to see whether there’s a dose-response shape, which is the kind of structured pattern that would give your endo and gynecologist something concrete to coordinate around rather than two separate specialists reading two separate charts.
The 40% that don’t spike is the signal I’d pull apart first. If baseline is already elevated going in from dose timing or a late meal, the bump might be real but fall below your HF_glucose_event threshold rather than being a genuinely flat episode.
the 60% correlation across 6 weeks is actually the part worth sitting with, bc that’s not noise. fwiw the cortisol mechanism is plausible but i’d also look at epinephrine as a co-trigger – vasomotor events spike both, and epi’s glycemic effect is faster than cortisol’s, which might explain the 20-30 min window you’re seeing. the endo/gyn coordination gap is real and it’s not just structural, it’s that neither specialty owns the glucose-hormone overlap when perimenopause and T2D are co-occurring. fezolinetant is interesting but the human data is still thin for metabolic secondary effects – worth asking your endo specifically whether reducing vasomotor frequency actually smooths the CGM curve before committing.